Global Recombinant Human Granulocyte Colony-Stimulating Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Recombinant Human Granulocyte Colony-Stimulating Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Report ID : 93073
Published On: Mar, 2022
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Recombinant Human Granulocyte Colony-Stimulating market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Recombinant Human Granulocyte Colony-Stimulating market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Chemotherapy Induced Neutropenia accounting for % of the Recombinant Human Granulocyte Colony-Stimulating global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Lenograstim (Granocyte) segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Recombinant Human Granulocyte Colony-Stimulating include Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, and Gensci, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Recombinant Human Granulocyte Colony-Stimulating market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Lenograstim (Granocyte)

Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

Others

Market segment by Application can be divided into

Chemotherapy Induced Neutropenia

Before Blood Donation

Stem Cell Transplants

Others

The key market players for global Recombinant Human Granulocyte Colony-Stimulating market are listed below:

Amgen

Qilu Pharmaceutical

Shijiazhuang Pharmaceutical

Kyowa Hakko Kirin

Gensci

Amoytop Biotech

Hangzhou Jiuyuan

Huaxin

Triprime

Sinovac

Zhaoke

Kawin

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Recombinant Human Granulocyte Colony-Stimulating product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Recombinant Human Granulocyte Colony-Stimulating, with price, sales, revenue and global market share of Recombinant Human Granulocyte Colony-Stimulating from 2019 to 2022.

Chapter 3, the Recombinant Human Granulocyte Colony-Stimulating competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Recombinant Human Granulocyte Colony-Stimulating breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Human Granulocyte Colony-Stimulating market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Human Granulocyte Colony-Stimulating.

Chapter 13, 14, and 15, to describe Recombinant Human Granulocyte Colony-Stimulating sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Recombinant Human Granulocyte Colony-Stimulating Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Lenograstim (Granocyte)

1.2.3 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

1.2.4 Others

1.3 Market Analysis by Application

1.3.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Chemotherapy Induced Neutropenia

1.3.3 Before Blood Donation

1.3.4 Stem Cell Transplants

1.3.5 Others

1.4 Global Recombinant Human Granulocyte Colony-Stimulating Market Size & Forecast

1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Volume (2017-2028)

1.4.3 Global Recombinant Human Granulocyte Colony-Stimulating Price (2017-2028)

1.5 Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity Analysis

1.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Total Production Capacity (2017-2028)

1.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Recombinant Human Granulocyte Colony-Stimulating Market Drivers

1.6.2 Recombinant Human Granulocyte Colony-Stimulating Market Restraints

1.6.3 Recombinant Human Granulocyte Colony-Stimulating Trends Analysis

2 Manufacturers Profiles

2.1 Amgen

2.1.1 Amgen Details

2.1.2 Amgen Major Business

2.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.1.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Qilu Pharmaceutical

2.2.1 Qilu Pharmaceutical Details

2.2.2 Qilu Pharmaceutical Major Business

2.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.2.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Shijiazhuang Pharmaceutical

2.3.1 Shijiazhuang Pharmaceutical Details

2.3.2 Shijiazhuang Pharmaceutical Major Business

2.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.3.4 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Kyowa Hakko Kirin

2.4.1 Kyowa Hakko Kirin Details

2.4.2 Kyowa Hakko Kirin Major Business

2.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.4.4 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Gensci

2.5.1 Gensci Details

2.5.2 Gensci Major Business

2.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.5.4 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 Amoytop Biotech

2.6.1 Amoytop Biotech Details

2.6.2 Amoytop Biotech Major Business

2.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.6.4 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7 Hangzhou Jiuyuan

2.7.1 Hangzhou Jiuyuan Details

2.7.2 Hangzhou Jiuyuan Major Business

2.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.7.4 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8 Huaxin

2.8.1 Huaxin Details

2.8.2 Huaxin Major Business

2.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.8.4 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9 Triprime

2.9.1 Triprime Details

2.9.2 Triprime Major Business

2.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.9.4 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10 Sinovac

2.10.1 Sinovac Details

2.10.2 Sinovac Major Business

2.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.10.4 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11 Zhaoke

2.11.1 Zhaoke Details

2.11.2 Zhaoke Major Business

2.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.11.4 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12 Kawin

2.12.1 Kawin Details

2.12.2 Kawin Major Business

2.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Product and Services

2.12.4 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Recombinant Human Granulocyte Colony-Stimulating Breakdown Data by Manufacturer

3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Recombinant Human Granulocyte Colony-Stimulating

3.4 Market Concentration Rate

3.4.1 Top 3 Recombinant Human Granulocyte Colony-Stimulating Manufacturer Market Share in 2021

3.4.2 Top 6 Recombinant Human Granulocyte Colony-Stimulating Manufacturer Market Share in 2021

3.5 Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Recombinant Human Granulocyte Colony-Stimulating Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Region

4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Region (2017-2028)

4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2028)

4.2 North America Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028)

4.3 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028)

4.4 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028)

4.5 South America Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028)

4.6 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Type (2017-2028)

5.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2017-2028)

5.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Application (2017-2028)

6.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2017-2028)

6.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2028)

7.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2028)

7.3 North America Recombinant Human Granulocyte Colony-Stimulating Market Size by Country

7.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Country (2017-2028)

7.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2028)

8.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2028)

8.3 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size by Country

8.3.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Country (2017-2028)

8.3.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2028)

9.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2028)

9.3 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Market Size by Region

9.3.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2028)

10.2 South America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2028)

10.3 South America Recombinant Human Granulocyte Colony-Stimulating Market Size by Country

10.3.1 South America Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Country (2017-2028)

10.3.2 South America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2028)

11.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2028)

11.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Market Size by Country

11.3.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Recombinant Human Granulocyte Colony-Stimulating and Key Manufacturers

12.2 Manufacturing Costs Percentage of Recombinant Human Granulocyte Colony-Stimulating

12.3 Recombinant Human Granulocyte Colony-Stimulating Production Process

12.4 Recombinant Human Granulocyte Colony-Stimulating Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Recombinant Human Granulocyte Colony-Stimulating Typical Distributors

13.3 Recombinant Human Granulocyte Colony-Stimulating Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Amgen Basic Information, Manufacturing Base and Competitors

Table 4. Amgen Major Business

Table 5. Amgen Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 6. Amgen Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 8. Qilu Pharmaceutical Major Business

Table 9. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 10. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. Shijiazhuang Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 12. Shijiazhuang Pharmaceutical Major Business

Table 13. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 14. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Kyowa Hakko Kirin Basic Information, Manufacturing Base and Competitors

Table 16. Kyowa Hakko Kirin Major Business

Table 17. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 18. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Gensci Basic Information, Manufacturing Base and Competitors

Table 20. Gensci Major Business

Table 21. Gensci Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 22. Gensci Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Amoytop Biotech Basic Information, Manufacturing Base and Competitors

Table 24. Amoytop Biotech Major Business

Table 25. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 26. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Hangzhou Jiuyuan Basic Information, Manufacturing Base and Competitors

Table 28. Hangzhou Jiuyuan Major Business

Table 29. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 30. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 31. Huaxin Basic Information, Manufacturing Base and Competitors

Table 32. Huaxin Major Business

Table 33. Huaxin Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 34. Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 35. Triprime Basic Information, Manufacturing Base and Competitors

Table 36. Triprime Major Business

Table 37. Triprime Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 38. Triprime Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 39. Sinovac Basic Information, Manufacturing Base and Competitors

Table 40. Sinovac Major Business

Table 41. Sinovac Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 42. Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 43. Zhaoke Basic Information, Manufacturing Base and Competitors

Table 44. Zhaoke Major Business

Table 45. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 46. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 47. Kawin Basic Information, Manufacturing Base and Competitors

Table 48. Kawin Major Business

Table 49. Kawin Recombinant Human Granulocyte Colony-Stimulating Product and Services

Table 50. Kawin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Price (USD/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 51. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Manufacturer (2019, 2020, 2021, and 2022) & (KG)

Table 52. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 53. Market Position of Manufacturers in Recombinant Human Granulocyte Colony-Stimulating, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 54. Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity by Company, (KG): 2020 VS 2021

Table 55. Head Office and Recombinant Human Granulocyte Colony-Stimulating Production Site of Key Manufacturer

Table 56. Recombinant Human Granulocyte Colony-Stimulating New Entrant and Capacity Expansion Plans

Table 57. Recombinant Human Granulocyte Colony-Stimulating Mergers & Acquisitions in the Past Five Years

Table 58. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2017-2022) & (KG)

Table 59. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2023-2028) & (KG)

Table 60. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2022) & (USD Million)

Table 61. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2023-2028) & (USD Million)

Table 62. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 63. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 64. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2017-2022) & (USD Million)

Table 65. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2023-2028) & (USD Million)

Table 66. Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2017-2022) & (USD/g)

Table 67. Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2023-2028) & (USD/g)

Table 68. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 69. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 70. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2017-2022) & (USD Million)

Table 71. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2023-2028) & (USD Million)

Table 72. Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2017-2022) & (USD/g)

Table 73. Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2023-2028) & (USD/g)

Table 74. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG)

Table 75. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2023-2028) & (KG)

Table 76. North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (USD Million)

Table 77. North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2023-2028) & (USD Million)

Table 78. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 79. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 80. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 81. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 82. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG)

Table 83. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2023-2028) & (KG)

Table 84. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (USD Million)

Table 85. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2023-2028) & (USD Million)

Table 86. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 87. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 88. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 89. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 90. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2017-2022) & (KG)

Table 91. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2023-2028) & (KG)

Table 92. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2022) & (USD Million)

Table 93. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2023-2028) & (USD Million)

Table 94. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 95. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 96. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 97. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 98. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG)

Table 99. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2023-2028) & (KG)

Table 100. South America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (USD Million)

Table 101. South America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2023-2028) & (USD Million)

Table 102. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 103. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 104. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 105. South America Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 106. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2017-2022) & (KG)

Table 107. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2023-2028) & (KG)

Table 108. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2022) & (USD Million)

Table 109. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2023-2028) & (USD Million)

Table 110. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG)

Table 111. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2023-2028) & (KG)

Table 112. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2017-2022) & (KG)

Table 113. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2023-2028) & (KG)

Table 114. Recombinant Human Granulocyte Colony-Stimulating Raw Material

Table 115. Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Raw Materials

Table 116. Direct Channel Pros & Cons

Table 117. Indirect Channel Pros & Cons

Table 118. Recombinant Human Granulocyte Colony-Stimulating Typical Distributors

Table 119. Recombinant Human Granulocyte Colony-Stimulating Typical Customers

List of Figures

Figure 1. Recombinant Human Granulocyte Colony-Stimulating Picture

Figure 2. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type in 2021

Figure 3. Lenograstim (Granocyte)

Figure 4. Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

Figure 5. Others

Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application in 2021

Figure 7. Chemotherapy Induced Neutropenia

Figure 8. Before Blood Donation

Figure 9. Stem Cell Transplants

Figure 10. Others

Figure 11. Global Recombinant Human Granulocyte Colony-Stimulating Revenue, (USD Million) & (KG): 2017 & 2021 & 2028

Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Sales (2017-2028) & (KG)

Figure 14. Global Recombinant Human Granulocyte Colony-Stimulating Price (2017-2028) & (USD/g)

Figure 15. Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity (2017-2028) & (KG)

Figure 16. Global Recombinant Human Granulocyte Colony-Stimulating Production Capacity by Geographic Region: 2022 VS 2028

Figure 17. Recombinant Human Granulocyte Colony-Stimulating Market Drivers

Figure 18. Recombinant Human Granulocyte Colony-Stimulating Market Restraints

Figure 19. Recombinant Human Granulocyte Colony-Stimulating Market Trends

Figure 20. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Manufacturer in 2021

Figure 21. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Manufacturer in 2021

Figure 22. Recombinant Human Granulocyte Colony-Stimulating Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 23. Top 3 Recombinant Human Granulocyte Colony-Stimulating Manufacturer (Revenue) Market Share in 2021

Figure 24. Top 6 Recombinant Human Granulocyte Colony-Stimulating Manufacturer (Revenue) Market Share in 2021

Figure 25. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2028)

Figure 26. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2028)

Figure 27. North America Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028) & (USD Million)

Figure 28. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028) & (USD Million)

Figure 29. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028) & (USD Million)

Figure 30. South America Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028) & (USD Million)

Figure 31. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue (2017-2028) & (USD Million)

Figure 32. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2028)

Figure 33. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2017-2028)

Figure 34. Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2017-2028) & (USD/g)

Figure 35. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 36. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2017-2028)

Figure 37. Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2017-2028) & (USD/g)

Figure 38. North America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2028)

Figure 39. North America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 40. North America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2028)

Figure 41. North America Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2028)

Figure 42. United States Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Canada Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Mexico Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2028)

Figure 46. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 47. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2028)

Figure 48. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2028)

Figure 49. Germany Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. France Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. United Kingdom Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Russia Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Italy Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2028)

Figure 55. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 56. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2028)

Figure 57. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2028)

Figure 58. China Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Japan Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Korea Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. India Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Australia Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. South America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2028)

Figure 65. South America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 66. South America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2028)

Figure 67. South America Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2028)

Figure 68. Brazil Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Argentina Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2028)

Figure 71. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2028)

Figure 72. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2028)

Figure 73. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2028)

Figure 74. Turkey Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Egypt Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Saudi Arabia Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. South Africa Recombinant Human Granulocyte Colony-Stimulating Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating in 2021

Figure 79. Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating

Figure 80. Recombinant Human Granulocyte Colony-Stimulating Industrial Chain

Figure 81. Sales Channel: Direct Channel vs Indirect Channel

Figure 82. Methodology

Figure 83. Research Process and Data Source

License Type

Quick Contact

Our Clients

Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz